Free Trial
NASDAQ:PTGX

Protagonist Therapeutics Q2 2024 Earnings Report

Protagonist Therapeutics logo
$44.39 -0.10 (-0.22%)
Closing price 04/28/2025 04:00 PM Eastern
Extended Trading
$45.32 +0.92 (+2.08%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protagonist Therapeutics EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.50
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Protagonist Therapeutics Revenue Results

Actual Revenue
$4.17 million
Expected Revenue
$40.00 million
Beat/Miss
Missed by -$35.83 million
YoY Revenue Growth
N/A

Protagonist Therapeutics Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Tuesday, August 6, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Protagonist Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Protagonist Therapeutics Earnings Headlines

New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
See More Protagonist Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Protagonist Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagonist Therapeutics and other key companies, straight to your email.

About Protagonist Therapeutics

Protagonist Therapeutics (NASDAQ:PTGX), a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

View Protagonist Therapeutics Profile

More Earnings Resources from MarketBeat